Last week, Pfizer (NYSE: PFE) announced that it was splitting its operating segments into three divisions. The company presently operates under a two-unit system: Innovative Health and Essential Health. Soon, however, it will instead sport an Innovative Medicines business, an Established Medicines unit, and a Consumer Healthcare segment. As this second reorganization in four years seems like a prelude to additional business development moves, this is an opportune time to consider if this big pharma stock is worth buying. Image Source: Getty Images.Continue reading